17 results on '"Ardon CB"'
Search Results
2. Clindamycin-Benzoyl Peroxide Gel Compared with Clindamycin Lotion for Hidradenitis Suppurativa: A Randomized Controlled Assessor-Blinded Intra-Patient Pilot Study.
- Author
-
Aarts P, Reeves JL, Ardon CB, van der Zee HH, and Prens EP
- Subjects
- Humans, Anti-Bacterial Agents therapeutic use, Benzoyl Peroxide therapeutic use, Clindamycin therapeutic use, Pain etiology, Pilot Projects, Severity of Illness Index, Treatment Outcome, Acne Vulgaris drug therapy, Hidradenitis Suppurativa drug therapy, Hidradenitis Suppurativa complications
- Abstract
Background: Antibiotic resistance is a major concern, especially in hidradenitis suppurativa (HS). However, antibiotics form a cornerstone in its treatment. Topical clindamycin is known to cause bacterial resistance but is still advised as monotherapy for the treatment of mild to moderate HS., Methods: This is a randomized, controlled, assessor-blinded, intra-patient pilot trial to compare the clinical efficacy of clindamycin-benzoyl peroxide gel with clindamycin lotion in patients with mild to moderate HS. Two contralateral body sites were randomized for treatment in each patient. The primary outcome was the difference in the International Hidradenitis Suppurativa Severity Score (IHS4) between the two groups after 12 weeks. Secondary objectives were feasibility of the intra-patient design, efficacy within treatment groups, effect on HS pain, HS itch, patient satisfaction, antibiotic resistance, and the prolonged efficacy after 16 weeks., Results: Ten patients were included, resulting in two groups of 10 treated body sites. No significant differences were found between the two groups for all measurements after 12 or 16 weeks, while both therapies led to an improvement in the IHS4, pain, and itch scores. A significant decrease was observed in the IHS4 for both the clindamycin lotion (-1.5; p < 0.05) and the clindamycin-benzoyl peroxide gel (-2; p < 0.01) after 16 weeks, and the pain scores were reduced from 7 to 2.5, p < 0.01 and 6.5 to 3, p = 0.03, respectively. Using the IHS4-55, we identified 50% of patients as responders in both groups after 12 weeks. The intra-patient design, however, unexpectedly appeared to hinder the inclusion of patients., Conclusion: Clindamycin-benzoyl peroxide gel showed favorable clinical efficacy results, similar to clindamycin lotion, suggesting that it could replace clindamycin lotion in the treatment of mild to moderate HS and to prevent antibiotic resistance. A larger controlled trial is needed to validate these results., (© 2023 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2023
- Full Text
- View/download PDF
3. Prevalence and Clinical Characteristics of Hidradenitis Suppurativa Phenotypes in a Large Dutch Cohort.
- Author
-
Dudink K, Aarts P, Ardon CB, Vossen ARJV, Koster SBL, Van den Bosch JF, Prens EP, and van der Zee HH
- Subjects
- Cohort Studies, Ethnicity, Humans, Phenotype, Prevalence, Hidradenitis Suppurativa epidemiology
- Published
- 2022
- Full Text
- View/download PDF
4. No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa.
- Author
-
Prens LM, Ardon CB, van Straalen KR, van der Zee HH, Seelen MAJ, Laman JD, Prens EP, Horváth B, and Damman J
- Subjects
- Adult, Case-Control Studies, Clinical Trials as Topic, Complement C5a immunology, Female, Hidradenitis Suppurativa blood, Humans, Male, Middle Aged, Complement Activation, Complement System Proteins, Hidradenitis Suppurativa immunology, Immunotherapy methods
- Published
- 2021
- Full Text
- View/download PDF
5. Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa.
- Author
-
Aarts P, Dudink K, Vossen ARJV, van Straalen KR, Ardon CB, Prens EP, and van der Zee HH
- Subjects
- Adalimumab therapeutic use, Anti-Bacterial Agents therapeutic use, Antibodies, Monoclonal, Humanized therapeutic use, CD40 Antigens antagonists & inhibitors, Epoxide Hydrolases antagonists & inhibitors, Etanercept therapeutic use, Hidradenitis Suppurativa physiopathology, Humans, Infliximab therapeutic use, Interleukin 1 Receptor Antagonist Protein therapeutic use, Interleukin-1 antagonists & inhibitors, Interleukin-17 antagonists & inhibitors, Interleukin-23 antagonists & inhibitors, Protein Kinase Inhibitors therapeutic use, Receptors, Interleukin-8A, Receptors, Interleukin-8B, Severity of Illness Index, Surgical Procedures, Operative, Thalidomide analogs & derivatives, Thalidomide therapeutic use, Biological Products therapeutic use, Complement Inactivating Agents therapeutic use, Hidradenitis Suppurativa drug therapy, Immunologic Factors therapeutic use, Janus Kinase Inhibitors therapeutic use, Tumor Necrosis Factor Inhibitors therapeutic use
- Abstract
Hidradenitis suppurativa (HS) is a chronic, recurrent, auto-inflammatory skin disease originating from the hair follicles. The typical inflammatory nodules, abscesses, and draining sinus tracts (tunnels) are characterized by a massive influx of neutrophils, macrophages, B-cells, plasma cells, T helper (Th)1, Th17 cells and upregulation of pro-inflammatory cytokines such as IL-1, IL-17, IL-12/23, and TNF-α. Over the last decades, several clinical trials evaluated the clinical efficacy of different biologics targeting these pro-inflammatory cytokines, in particular TNF-α and IL-1. However, adalimumab is still the only registered drug for HS. This review discusses biologics and small molecules with high level of evidence for their clinical application, provides guidance on when and how to use these biologics and small molecules in clinical practice, and elaborates on the combination with medical and surgical treatment options beyond the current guidelines. Furthermore this review provides an overview of potential biologics and small molecules currently under investigation for novel targets in HS such as IL-36, C5a, Janus kinase family members, CD-40, LTA4 and CXCR1/2., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
6. Body mass index at the onset of hidradenitis suppurativa.
- Author
-
van Straalen KR, Vanlaerhoven AMJD, Ardon CB, and van der Zee HH
- Subjects
- Body Mass Index, Humans, Quality of Life, Severity of Illness Index, Hidradenitis Suppurativa diagnosis
- Published
- 2021
- Full Text
- View/download PDF
7. Hidradenitis suppurativa - Body-Mass-Index zu Beginn der Erkrankung.
- Author
-
van Straalen KR, Vanlaerhoven AMJD, Ardon CB, and van der Zee HH
- Published
- 2021
- Full Text
- View/download PDF
8. Noninvasive assessment of cytokine and antimicrobial peptide levels in hidradenitis suppurativa using transdermal analysis patches.
- Author
-
Ardon CB, Wang C, Prens EP, and van Straalen KR
- Subjects
- Cytokines, Humans, Pore Forming Cytotoxic Proteins, Severity of Illness Index, Transdermal Patch, Hidradenitis Suppurativa drug therapy
- Published
- 2021
- Full Text
- View/download PDF
9. Nicotine Dependency and Readiness to Quit Smoking among Patients with Hidradenitis Suppurativa.
- Author
-
Vossen ARJV, van Straalen KR, Swolfs EFH, van den Bosch JF, Ardon CB, and van der Zee HH
- Subjects
- Adult, Case-Control Studies, Cross-Sectional Studies, Female, Humans, Male, Middle Aged, Netherlands, Hidradenitis Suppurativa etiology, Smoking adverse effects, Smoking Cessation, Tobacco Use Disorder complications
- Published
- 2021
- Full Text
- View/download PDF
10. Characterization of perianal fistulas in patients with hidradenitis suppurativa.
- Author
-
Scholtes VC, Ardon CB, van Straalen KR, Dwarkasing RS, Boer J, and van der Zee HH
- Subjects
- Adult, Cutaneous Fistula diagnostic imaging, Female, Hidradenitis Suppurativa diagnostic imaging, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Rectal Fistula diagnostic imaging, Cutaneous Fistula etiology, Hidradenitis Suppurativa complications, Rectal Fistula etiology
- Published
- 2019
- Full Text
- View/download PDF
11. The anti-inflammatory potency of biologics targeting tumour necrosis factor-α, interleukin (IL)-17A, IL-12/23 and CD20 in hidradenitis suppurativa: an ex vivo study.
- Author
-
Vossen ARJV, Ardon CB, van der Zee HH, Lubberts E, and Prens EP
- Subjects
- Adult, Anti-Inflammatory Agents therapeutic use, Antigens, CD20 immunology, Antigens, CD20 metabolism, Antimicrobial Cationic Peptides antagonists & inhibitors, Antimicrobial Cationic Peptides immunology, Antimicrobial Cationic Peptides metabolism, Biological Products therapeutic use, Biopsy, Female, Healthy Volunteers, Hidradenitis Suppurativa immunology, Hidradenitis Suppurativa pathology, Hidradenitis Suppurativa surgery, Humans, Interleukin-12 Subunit p40 antagonists & inhibitors, Interleukin-12 Subunit p40 immunology, Interleukin-12 Subunit p40 metabolism, Interleukin-17 antagonists & inhibitors, Interleukin-17 immunology, Interleukin-17 metabolism, Male, Middle Aged, Organ Culture Techniques, Prednisolone therapeutic use, Skin immunology, Skin metabolism, Skin pathology, Tumor Necrosis Factor-alpha antagonists & inhibitors, Tumor Necrosis Factor-alpha immunology, Tumor Necrosis Factor-alpha metabolism, Anti-Inflammatory Agents pharmacology, Biological Products pharmacology, Hidradenitis Suppurativa drug therapy, Prednisolone pharmacology, Skin drug effects
- Abstract
Background: Biologics targeting inflammatory mediators can achieve clinical improvements in hidradenitis suppurativa (HS). However, their clinical efficacy shows great interpatient variability in daily practice., Objectives: To investigate the anti-inflammatory potency of a selection of currently available biologics and prednisolone for the treatment of HS in an ex vivo skin culture system using lesional HS biopsies., Methods: Lesional skin samples from 10 patients with HS and skin samples from five healthy controls were cultured ex vivo and exposed to prednisolone or biologics targeting tumour necrosis factor (TNF)-α, interleukin (IL)-17A, IL-12/23p40 or CD20 (adalimumab, infliximab, secukinumab, ustekinumab and rituximab, respectively). Real-time quantitative polymerase chain reaction and cytokine bead arrays were used to measure the inhibitory effect of the biologics on cytokines and antimicrobial peptides (AMPs)., Results: The relative mRNA expression of all tested cytokines and AMPs was significantly downregulated by all anti-inflammatory agents (P < 0·001). The protein production of the proinflammatory cytokines TNF-α, interferon γ, IL-1β, IL-6 and IL-17A was significantly inhibited by adalimumab, infliximab, ustekinumab, prednisolone (all P < 0·001) and rituximab (P = 0·0071), but not by secukinumab (P = 0·0663). On both mRNA and protein levels, adalimumab, infliximab and prednisolone reduced the levels of a broader mix of individual cytokines than secukinumab, ustekinumab and rituximab. Moreover, a significant inhibitory effect on mRNA expression levels of inflammatory markers in healthy control skin was observed only for TNF-α inhibitors (P < 0·001) and prednisolone (P = 0·0015)., Conclusions: This ex vivo study suggests that TNF-α inhibitors and prednisolone are the most powerful inhibitors of proinflammatory cytokines and AMPs in HS lesional skin, which concurs with our clinical experience in patients with HS., (© 2019 The Authors. British Journal of Dermatology published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.)
- Published
- 2019
- Full Text
- View/download PDF
12. High prevalence of hidradenitis suppurativa in patients with perianal fistula.
- Author
-
Ardon CB, Molenaar C, van Straalen KR, Scholtes VC, Prens EP, and van der Zee HH
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Prevalence, Hidradenitis Suppurativa epidemiology, Hidradenitis Suppurativa etiology, Rectal Fistula complications
- Abstract
Background: Perianal fistula is an abnormal communication between the anal canal and perianal skin. Hidradenitis suppurativa (HS) is a chronic, auto-inflammatory skin disease in the intertriginous body areas, presenting with recurring abscesses, inflammatory nodules, and sinus tracts. The aim of this study was to determine the prevalence of HS in patients with a perianal fistula., Methods: All patients with perianal fistula visiting a specialized proctology clinic between July and September 2017 were included and asked a validated diagnostic question for HS. Subsequently, physical examination was performed to objectively assess the diagnosis and relevant patient characteristics., Results: In 6.6% (8/122) of patients, HS was diagnosed outside the perianal region. Four of these patients were newly diagnosed. The fistulas in HS patients were classified as a superficial fistula (three), a blind ending fistula (two), and a transsphincteric fistula (two). One patient had more than one type of fistula., Conclusion: The prevalence of HS in patients with a perianal fistula is at least 6.6%. This is higher than the prevalence reported in the general European population (1%) suggesting an association between perianal fistulas and HS. We stress the importance to screen for HS in patients with perianal fistulas in order to start appropriate anti-inflammatory treatment to reduce symptoms and disease progression.
- Published
- 2019
- Full Text
- View/download PDF
13. Virulent Staphylococcus lugdunensis with limited genetic diversity in hidradenitis suppurativa lesions.
- Author
-
Ardon CB, Prens EP, Tkadlec J, Fuursted K, Abourayale S, Jemec GBE, and Jenssen H
- Subjects
- Anti-Bacterial Agents pharmacology, Biofilms, Case-Control Studies, Humans, Microbial Sensitivity Tests, Staphylococcus lugdunensis drug effects, Staphylococcus lugdunensis genetics, Virulence, Genes, Bacterial, Genetic Variation, Hidradenitis Suppurativa microbiology, Staphylococcus lugdunensis isolation & purification, Staphylococcus lugdunensis pathogenicity
- Published
- 2019
- Full Text
- View/download PDF
14. Correlation of the refined Hurley classification for hidradenitis suppurativa with patient-reported quality of life and objective disease severity assessment.
- Author
-
Rondags A, van Straalen KR, van Hasselt JR, Janse IC, Ardon CB, Vossen ARJV, Prens EP, van der Zee HH, and Horváth B
- Subjects
- Adult, Cross-Sectional Studies, Feasibility Studies, Female, Hidradenitis Suppurativa complications, Humans, Longitudinal Studies, Male, Middle Aged, Netherlands, Registries statistics & numerical data, Hidradenitis Suppurativa diagnosis, Patient Reported Outcome Measures, Quality of Life, Severity of Illness Index
- Abstract
Background: Hidradenitis suppurativa (HS) is a chronic, debilitating, heterogeneous disease requiring different treatment approaches. Recently, we refined the classic Hurley classification into a seven-stage classification in order to guide these treatment choices. This new classification subdivides Hurley stage I and II into three substages, namely mild (A), moderate (B) and severe (C) HS disease. Hurley stage III is not subcategorized and is always severe., Objectives: To investigate the correlation between the given severity grades of Hurley I and Hurley II in the refined Hurley classification, and the patient-reported quality of life and physician-assessed objective severity score., Materials and Methods: In this cross-sectional study, patients with HS participating in the observational cohorts of two Dutch tertiary referral centres were included before June 2017. The patient-reported Dermatology Life Quality Index (DLQI) and physician-assessed International HS Severity Score System (IHS4) scores were compared between the refined Hurley stages., Results: In total, 433 patients were analysed. DLQI and IHS4 scores increased within Hurley stage I and II from A through C. There was a significant positive correlation of DLQI and IHS4 with increasing refined Hurley substages [refined Hurley stage I (A, B and C) to DLQI: r
s = 0·259, P < 0·001 and refined Hurley stage II (A, B and C) to DLQI: rs = 0·185, P = 0·010; refined Hurley stage I (A, B and C) to IHS4: rs = 0·603, P < 0·001 and refined Hurley stage II (A, B and C) to IHS4: rs = 0·532, P < 0·001]., Conclusions: The refined Hurley classification accurately correlates with HS severity assessed by both patients and clinicians. Therefore, the refined Hurley classification is a useful tool for the quick assessment of severity in HS., (© 2018 British Association of Dermatologists.)- Published
- 2019
- Full Text
- View/download PDF
15. Biofilm production and antibiotic susceptibility of Staphylococcus epidermidis strains from Hidradenitis Suppurativa lesions.
- Author
-
Ardon CB, Prens EP, Fuursted K, Ejaz RN, Shailes J, Jenssen H, and Jemec GBE
- Subjects
- Biofilms growth & development, Clindamycin pharmacology, Doxycycline pharmacology, Drug Resistance, Bacterial, Humans, Microbial Sensitivity Tests, Rifampin pharmacology, Staphylococcus epidermidis isolation & purification, Tetracycline pharmacology, Anti-Bacterial Agents pharmacology, Biofilms drug effects, Hidradenitis Suppurativa microbiology, Staphylococcus epidermidis drug effects, Staphylococcus epidermidis growth & development
- Abstract
Background: An aberrant interaction between commensal skin bacteria and the host skin immune system is considered important in the pathogenesis of hidradenitis suppurativa (HS)., Objective: In this study, we investigated the antibiotic susceptibility and biofilm-forming capabilities of S. epidermidis strains isolated from HS patients., Methods: Skin biopsies were taken from active HS lesions such as inflammatory nodules and/or sinuses and non-involved skin from 26 patients and cultured under optimal microbiological conditions for 24 h. Planktonic growth, biofilm production, antibiotic susceptibility and biofilm eradication by clindamycin, doxycycline, rifampicin and tetracycline were tested including a laboratory control strain of S. epidermidis for reference., Results: Staphylococcus epidermidis was cultured in 16 of 26 HS patients (62%). In total 27 different S. epidermidis isolates were identified; 16 (59%) from non-involved skin and 11 (41%) from HS lesions. All bacterial strains showed planktonic growth. Twenty-four of 27 (89%) isolates were strong biofilm producers in vitro. The biofilm-forming capability varied amongst the strains from non-involved skin and lesional skin. Twenty-four strains had an intermediate to resistant antibiotic susceptibility to clindamycin (89%). Rifampicin was the most effective antibiotic at inhibiting planktonic growth and at eradication of biofilm (P < 0.05)., Conclusion: We observed a slight increase in S. epidermidis virulence, characterized by resistance to commonly used antibiotics, increased biofilm production and resistance to biofilm eradication. In particular, the reduced sensitivity to tetracycline and clindamycin, two standard antibiotics in the treatment of HS, is alarming. Rifampicin, also important in HS treatment, showed the greatest efficacy at eradicating the biofilm at low MIC concentrations., (© 2018 European Academy of Dermatology and Venereology.)
- Published
- 2019
- Full Text
- View/download PDF
16. Neurotensin, substance P, and insulin enhance cell migration.
- Author
-
Mouritzen MV, Abourayale S, Ejaz R, Ardon CB, Carvalho E, Dalgaard LT, Roursgaard M, and Jenssen H
- Subjects
- Cell Line, Cytokines biosynthesis, Humans, Keratinocytes cytology, Keratinocytes drug effects, Staphylococcus lugdunensis isolation & purification, Cell Movement drug effects, Insulin pharmacology, Neurotensin pharmacology, Substance P pharmacology
- Abstract
Neurotensin, substance P, and insulin have been demonstrated to improve wound healing in vivo. However, the mechanism behind their effect is still not fully understood. This study investigates the effects leading to enhanced scratch closure by these peptides in vitro. The skin keratinocyte cell line, HaCaT, was used to test scratch closure effects of the peptides and alterations of cytokine levels. HUVEC cells were used to test the angiogenic effect of the peptides. Furthermore, clinical isolates of Staphylococcus lugdunensis were used to examine the potential antimicrobial activity of each peptide. Our results demonstrate that neurotensin, substance P, and insulin had significant migratory effects in scratch assays were neurotensin had the lowest effect. Furthermore, we investigated use of the peptides in combination. When substance P was used in combination with neurotensin, the cell migratory capacity was decreased, and the peptides showed a negative correlation (r = -0.298, P < .001). Neurotensin and insulin significantly increased levels of monocyte chemoattractant protein-1 (P < .001) secreted from white blood cells, whereas substance P showed a tendency. Interestingly, neurotensin increased the level of monocyte chemoattractant protein-1 significantly compared to substance P (P < .01). Additionally, the peptides decreased TNFα mRNA levels (P < .001) in HaCaT cells, whereas only neurotensin and insulin decreased IL-8 mRNA (P < .001) but had no significant effect on IL-6 mRNA levels. Surprisingly, substance P increased IL-6 mRNA 9-fold (P < .001). Furthermore, we demonstrate that the peptides increased angiogenesis in the HUVEC cells (P < .001). Finally, S. lugdunensis isolates were not susceptible to the peptides. We demonstrate that the peptides worked differently on HaCaT cells, but substance P acted differently than neurotensin on cytokine levels expression as well as on migration of HaCaT cells. On the contrary, neurotensin and insulin worked similarly. All of these aspects are crucial for proper wound healing, and the results suggest multiple mechanisms for wound-healing properties of these peptides., (© 2018 European Peptide Society and John Wiley & Sons, Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
17. Hurley III Hidradenitis Suppurativa Has an Aggressive Disease Course.
- Author
-
Vanlaerhoven AMJD, Ardon CB, van Straalen KR, Vossen ARJV, Prens EP, and van der Zee HH
- Subjects
- Humans, Retrospective Studies, Time Factors, Disease Progression, Hidradenitis Suppurativa classification, Severity of Illness Index
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.